A fever and a nasty cough can be symptoms of a range of respiratory illnesses. An antigen test that narrows down the culprits ...

We recently compiled a list of the David Einhorn’s Stock Portfolio: Top 10 Stocks to Buy. In this article, we are going to ...

The approval of Hympavzi Friday was a dose of good news for Pfizer, which is dealing with research setbacks and a challenge from an activist investor.

Joe Montana chats with Mackenzie Salmon about his partnership with Pfizer and how he keeps himself healthy now that he's over ...

Wilson explains how Pfizer's decision to withdraw Oxbryta from global markets could affect the sickle cell community.

With valuations growing across the stock market and the biopharma sector, it's only natural for value-sensitive investors to ...

All the companies have skin in the game for clotting/bleeding disorders. The BMS-Pfizer Alliance market Factor Xa blood ...

The activist investment firm Starboard Value has launched a proxy fight again Pfizer, questioning the company’s management ...

In the assessment of 12-month price targets, analysts unveil insights for ICU Medical, presenting an average target of $169.5 ...

Pfizer's Hympavzi receives FDA approval as the first anti-TFPI therapy for hemophilia A and B. This subcutaneous, once-weekly ...

AbbVie has been reporting an earnings decline because its former lead drug, Humira, lost patent-protected market exclusivity ...

Barely three years since its coronavirus vaccine helped stem the pandemic, Pfizer’s stock has lost 50 percent of its value ...